Escherichia coli Infections – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Escherichia coli Infections – Pipeline Review, H1 2017’, provides an overview of the Escherichia coli Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Escherichia coli Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Escherichia coli Infections

The report reviews pipeline therapeutics for Escherichia coli Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Escherichia coli Infections therapeutics and enlists all their major and minor projects

The report assesses Escherichia coli Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Escherichia coli Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Escherichia coli Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Escherichia coli Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abgentis Ltd

Adenium Biotech ApS

AstraZeneca Plc

Atterx Biotherapeutics Inc

AvidBiotics Corp

Cellceutix Corp

ContraFect Corp

Debiopharm International SA

Emergent BioSolutions Inc

F. Hoffmann-La Roche Ltd

GangaGen Inc

Hsiri Therapeutics LLC

ImmunoClin Corp

Immuron Ltd

Johnson & Johnson

Kyorin Pharmaceutical Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Microbiotix Inc

Nabriva Therapeutics AG

Navigen Inc

Nosopharm SAS

Novabiotics Ltd

Paratek Pharmaceuticals Inc

Pherecydes Pharma SA

Phico Therapeutics Ltd

Recce Ltd

Sealife PHARMA GMBH

Soligenix Inc

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Escherichia coli Infections - Overview 8

Escherichia coli Infections - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 16

Products under Development by Universities/Institutes 19

Escherichia coli Infections - Therapeutics Assessment 21

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Escherichia coli Infections - Companies Involved in Therapeutics Development 29

Abgentis Ltd 29

Adenium Biotech ApS 29

AstraZeneca Plc 30

Atterx Biotherapeutics Inc 30

AvidBiotics Corp 31

Cellceutix Corp 31

ContraFect Corp 32

Debiopharm International SA 32

Emergent BioSolutions Inc 33

F. Hoffmann-La Roche Ltd 33

GangaGen Inc 34

Hsiri Therapeutics LLC 34

ImmunoClin Corp 35

Immuron Ltd 35

Johnson & Johnson 36

Kyorin Pharmaceutical Co Ltd 36

Melinta Therapeutics Inc 37

Merck & Co Inc 37

Microbiotix Inc 38

Nabriva Therapeutics AG 38

Navigen Inc 39

Nosopharm SAS 39

Novabiotics Ltd 40

Paratek Pharmaceuticals Inc 40

Pherecydes Pharma SA 41

Phico Therapeutics Ltd 41

Recce Ltd 42

Sealife PHARMA GMBH 42

Soligenix Inc 43

Syntiron LLC 43

Tetraphase Pharmaceuticals Inc 44

Escherichia coli Infections - Drug Profiles 45

A-3APO - Drug Profile 45

AA-139 - Drug Profile 47

AM-8722 - Drug Profile 48

ASN-200 - Drug Profile 49

AvR2-V10 - Drug Profile 50

BC-7634 - Drug Profile 52

BC-9074 - Drug Profile 53

BC-9529 - Drug Profile 54

BC-9563 - Drug Profile 55

BIZ-20131 - Drug Profile 56

BIZ-20132 - Drug Profile 57

BIZ-20133 - Drug Profile 58

CA-824 - Drug Profile 59

CC-1807 - Drug Profile 60

CF-301 - Drug Profile 61

Debio-1454 - Drug Profile 65

dusquetide - Drug Profile 66

EBX-004 - Drug Profile 72

Escherichia coli (whole cell) vaccine - Drug Profile 73

Escherichia coli vaccine - Drug Profile 74

Escherichia coli vaccine - Drug Profile 75

ETEC [strain B7A] vaccine - Drug Profile 76

ETEC vaccine - Drug Profile 77

EV-035 - Drug Profile 78

GN-4474 - Drug Profile 80

GNeg Snare - Drug Profile 81

GYR-12 - Drug Profile 82

HT-07 - Drug Profile 83

infectious disease vaccine - Drug Profile 84

interleukin-22 - Drug Profile 85

JNJ-63871860 - Drug Profile 86

JSM-11 - Drug Profile 88

MBX-2319 - Drug Profile 89

MDN-0057 - Drug Profile 90

mirandamycin - Drug Profile 92

NBTI-5463 - Drug Profile 93

NOSO-95179 - Drug Profile 94

NP-432 - Drug Profile 95

omadacycline tosylate - Drug Profile 96

Onc-72 - Drug Profile 106

P-100031 - Drug Profile 107

Peptides for Infectious Diseases - Drug Profile 108

Polysaccharides for Bacterial Infections - Drug Profile 109

PP-0121 - Drug Profile 110

Proteins for Infectious Diseases - Drug Profile 112

PT-5 - Drug Profile 113

RECCE-327 - Drug Profile 114

Recombinant Protein for Escherichia Coli Infections - Drug Profile 116

RX-05 - Drug Profile 117

RXP-873 - Drug Profile 118

SE-1 - Drug Profile 119

Shigetec - Drug Profile 120

SLP-0901 - Drug Profile 121

SLP-0905 - Drug Profile 122

Small Molecule for Malaria and Bacterial Infections - Drug Profile 123

Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile 124

Small Molecule to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile 125

Small Molecules for Escherichia coli Infections - Drug Profile 126

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 127

Small Molecules to Inhibit DbpA for Escherichia coli Infections - Drug Profile 128

Small Molecules to Inhibit RecA for Bacterial Infections - Drug Profile 129

SPR-741 - Drug Profile 130

Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 133

Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 134

Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections - Drug Profile 135

Synthetic Peptides for Escherichia Coli Infections - Drug Profile 136

Synthetic Peptides for Infectious Disease - Drug Profile 137

TN-5 - Drug Profile 138

TP-6076 - Drug Profile 139

Escherichia coli Infections - Dormant Projects 140

Escherichia coli Infections - Discontinued Products 143

Escherichia coli Infections - Product Development Milestones 144

Featured News & Press Releases 144

Appendix 147

Methodology 147

Coverage 147

Secondary Research 147

Primary Research 147

Expert Panel Validation 147

Contact Us 147

Disclaimer 148

List of Tables

List of Tables

Number of Products under Development for Escherichia coli Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Escherichia coli Infections – Pipeline by Abgentis Ltd, H1 2017

Escherichia coli Infections – Pipeline by Adenium Biotech ApS, H1 2017

Escherichia coli Infections – Pipeline by AstraZeneca Plc, H1 2017

Escherichia coli Infections – Pipeline by Atterx Biotherapeutics Inc, H1 2017

Escherichia coli Infections – Pipeline by AvidBiotics Corp, H1 2017

Escherichia coli Infections – Pipeline by Cellceutix Corp, H1 2017

Escherichia coli Infections – Pipeline by ContraFect Corp, H1 2017

Escherichia coli Infections – Pipeline by Debiopharm International SA, H1 2017

Escherichia coli Infections – Pipeline by Emergent BioSolutions Inc, H1 2017

Escherichia coli Infections – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Escherichia coli Infections – Pipeline by GangaGen Inc, H1 2017

Escherichia coli Infections – Pipeline by Hsiri Therapeutics LLC, H1 2017

Escherichia coli Infections – Pipeline by ImmunoClin Corp, H1 2017

Escherichia coli Infections – Pipeline by Immuron Ltd, H1 2017

Escherichia coli Infections – Pipeline by Johnson & Johnson, H1 2017

Escherichia coli Infections – Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Escherichia coli Infections – Pipeline by Melinta Therapeutics Inc, H1 2017

Escherichia coli Infections – Pipeline by Merck & Co Inc, H1 2017

Escherichia coli Infections – Pipeline by Microbiotix Inc, H1 2017

Escherichia coli Infections – Pipeline by Nabriva Therapeutics AG, H1 2017

Escherichia coli Infections – Pipeline by Navigen Inc, H1 2017

Escherichia coli Infections – Pipeline by Nosopharm SAS, H1 2017

Escherichia coli Infections – Pipeline by Novabiotics Ltd, H1 2017

Escherichia coli Infections – Pipeline by Paratek Pharmaceuticals Inc, H1 2017

Escherichia coli Infections – Pipeline by Pherecydes Pharma SA, H1 2017

Escherichia coli Infections – Pipeline by Phico Therapeutics Ltd, H1 2017

Escherichia coli Infections – Pipeline by Recce Ltd, H1 2017

Escherichia coli Infections – Pipeline by Sealife PHARMA GMBH, H1 2017

Escherichia coli Infections – Pipeline by Soligenix Inc, H1 2017

Escherichia coli Infections – Pipeline by Syntiron LLC, H1 2017

Escherichia coli Infections – Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017

Escherichia coli Infections – Dormant Projects, H1 2017

Escherichia coli Infections – Dormant Projects, H1 2017 (Contd..1), H1 2017

Escherichia coli Infections – Dormant Projects, H1 2017 (Contd..2), H1 2017

Escherichia coli Infections – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Escherichia coli Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports